Average time (in quarters) until nursing home admission: results of OLS regression analyses.
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7
Intercept 32.66 6.31 -22.42 -18.46 17.63* -130.13 -45.12
[-143.84; 209.16] [ -5.24; 17.86] [-72.64; 27.80] [-124.69; 87.76] [13.68; 21.57] [-359.42; 99.16] [-102.49; 12.24]
Composition: General practitioners -0.05 0.92 0.26
[ -1.81; 1.72] [ -1.07; 2.90] [ -0.07; 0.60]
Composition: Ophtalmologists -0.03 0.13
[ -2.21; 2.14] [ -2.15; 2.41]
Composition: Surgeons -0.17 1.57 0.68*
[ -2.08; 1.74] [ -0.53; 3.67] [ 0.05; 1.31]
Composition: Multidisciplinary practices -0.42 1.12 0.42*
[ -2.19; 1.34] [ -0.85; 3.09] [ 0.18; 0.66]
Composition: Therapists -0.29 1.10 0.42*
[ -2.05; 1.48] [ -0.87; 3.07] [ 0.19; 0.66]
Composition: Internists -1.20 0.71
[ -3.04; 0.64] [ -1.35; 2.76]
Composition: Orthopedics -1.04 1.04
[ -3.10; 1.01] [ -1.10; 3.19]
Composition: Psychologists and psychotherapists -0.87 1.11 0.44*
[ -2.62; 0.89] [ -0.85; 3.08] [ 0.10; 0.79]
Composition: Other disciplines -0.24 1.21 0.49*
[ -2.02; 1.54] [ -0.77; 3.20] [ 0.22; 0.77]
Composition: Urologists 0.67 2.18 1.43*
[ -1.61; 2.94] [ -0.22; 4.58] [ 0.17; 2.69]
Composition: Rehabilitation facilities 0.62 1.68 1.27*
[ -1.17; 2.41] [ -0.29; 3.66] [ 0.37; 2.17]
Composition: Hospitals -0.06 0.67
[ -1.85; 1.73] [ -1.46; 2.80]
Composition: Proportion of care-dependent persons in cluster 0.33* 0.50* 0.54*
[ 0.15; 0.51] [ 0.21; 0.79] [ 0.32; 0.76]
Composition: Logarithm of number of providers in cluster 2.13* 1.71* 1.76*
[ 1.48; 2.78] [ 0.87; 2.54] [ 1.08; 2.45]
No. of Comorbidities -20.15 -26.54* -18.14*
[-40.38; 0.09] [ -49.11; -3.98] [ -26.82; -9.47]
COC Asthma 0.67 -1.06 -1.22*
[ -0.84; 2.17] [ -2.55; 0.43] [ -2.27; -0.17]
SECON Asthma -0.95 -0.34
[ -1.93; 0.03] [ -1.29; 0.62]
UPC Asthma 0.34 2.15 2.16*
[ -1.92; 2.59] [ -0.09; 4.39] [ 0.59; 3.73]
COC COPD -7.51* -0.50
[ -10.54; -4.47] [ -3.91; 2.92]
SECON COPD 2.10* 1.32 1.04*
[ 0.70; 3.49] [ -0.12; 2.77] [ 0.15; 1.94]
UPC COPD 7.33* -1.22 -1.59*
[ 3.46; 11.20] [ -5.44; 2.99] [ -2.63; -0.56]
COC Dementia -1.49 -0.10
[ -4.78; 1.79] [ -3.14; 2.94]
SECON Dementia 2.61* 0.45
[ 1.17; 4.05] [ -0.94; 1.85]
UPC Dementia -0.53 -0.23
[ -4.71; 3.66] [ -4.13; 3.66]
COC Diabetes 6.16* 1.35 0.60
[ 3.27; 9.04] [ -1.91; 4.60] [ -0.17; 1.37]
SECON Diabetes -2.81* -1.05 -0.75
[ -4.06; -1.56] [ -2.43; 0.32] [ -1.71; 0.22]
UPC Diabetes -5.33* -0.70
[ -8.62; -2.04] [ -4.31; 2.90]
COC Heart Failure 0.40 -0.28
[ -1.22; 2.01] [ -1.85; 1.28]
SECON Heart Failure -0.66 -0.21
[ -1.45; 0.12] [ -1.10; 0.67]
UPC Heart Failure -0.06 0.63
[ -2.12; 2.00] [ -1.32; 2.58]
Asthma: Prevalence -0.02 -0.08
[ -0.68; 0.65] [ -0.87; 0.71]
Asthma: Spirometry -0.01 0.01
[ -0.10; 0.07] [ -0.11; 0.13]
Asthma: Inhalative medication 0.01 0.04
[ -0.12; 0.13] [ -0.10; 0.18]
Asthma: ICS -0.04 -0.00
[ -0.15; 0.06] [ -0.12; 0.12]
Medication: PRISCUS -0.46* -0.37
[ -0.89; -0.04] [ -0.89; 0.15]
Medication: Beta-Blocker after myocardial infarction -0.08 -0.07
[ -0.37; 0.22] [ -0.39; 0.24]
Medication: ACE-inhibitor upon hypertension and renal insufficiency a -0.30 -0.15
[ -0.61; 0.02] [ -0.46; 0.16]
Medication: ACE-inhibitor upon heart failure -0.17 -0.19 -0.36*
[ -0.53; 0.20] [ -0.57; 0.18] [ -0.58; -0.14]
Medication: Beta-blocker upon asthma -0.22 -0.02
[ -0.50; 0.06] [ -0.31; 0.27]
Medication: Eletrolyte check upon diuretics -0.11 -0.07
[ -0.28; 0.06] [ -0.25; 0.11]
Medication: Polypharmacy 0.56* 0.62* 0.34*
[ 0.21; 0.92] [ 0.15; 1.10] [ 0.10; 0.59]
Ambulatory care sensitive cases 0.48 -2.13* -1.87*
[-0.75; 1.72] [ -4.05; -0.21] [ -3.27; -0.47]
COPD: Prevalence -0.08 0.48 0.32
[ -0.51; 0.35] [ -0.01; 0.98] [ -0.04; 0.68]
COPD: Inhalative medication -0.20 -0.35* -0.33*
[ -0.45; 0.06] [ -0.63; -0.07] [ -0.51; -0.15]
COPD: Acute inpatient treatment -0.74 1.11 1.54
[-2.21; 0.73] [ -0.72; 2.94] [ -0.01; 3.08]
COPD: Respiratory therapy -0.08 -0.39 -0.38*
[ -0.39; 0.24] [ -0.79; 0.00] [ -0.68; -0.07]
COPD: influenca vaccination 0.23 0.37
[ -0.84; 1.29] [ -0.65; 1.40]
COPD: Specific beta-blocker therapy 0.12 -0.11
[ -0.15; 0.39] [ -0.41; 0.18]
COPD: Specific anticholinergic therapy 0.04 0.08
[ -0.19; 0.27] [ -0.16; 0.32]
COPD: Oral corticosteroids 0.07 0.03
[ -0.27; 0.41] [ -0.33; 0.39]
CVD: Prevalence hypertension 0.44* 0.27 0.38*
[ 0.12; 0.76] [ -0.11; 0.66] [ 0.11; 0.64]
CVD: Medication for hypertension -0.63* -0.49 -0.32
[ -1.13; -0.14] [ -1.03; 0.05] [ -0.78; 0.13]
CVD: Prevalence heart failure 0.73 0.21
[ -0.03; 1.48] [ -0.70; 1.12]
CVD: Echocardiography upon heart failure 0.01 -0.00
[ -0.09; 0.10] [ -0.10; 0.09]
CVD: 12-lead ECG upon heart failure 0.00 -0.03
[ -0.08; 0.09] [ -0.11; 0.06]
CVD: ACE-inhibiter upon heart failure 0.21 0.20 0.25*
[ -0.12; 0.54] [ -0.15; 0.56] [ 0.02; 0.49]
CVD: Beta-blocker upon heart failure -0.10 0.00
[ -0.34; 0.15] [ -0.25; 0.25]
CVD: Anticoagulant upon artrial fibrillation and heart failure 0.14 0.08
[ -0.12; 0.41] [ -0.18; 0.35]
CVD: Referral to cardiologist upon heart failure 0.07* 0.04
[ 0.00; 0.13] [ -0.03; 0.10]
CVD: Acute inpatient treatment of heart failure -0.07 -0.04
[-0.28; 0.13] [ -0.29; 0.22]
CVD: Apoplexy treatment in stroke unit 0.20 0.10
[ -0.32; 0.73] [ -0.43; 0.64]
CVD: Platelet aggregation inhibitor upon stable chronic coronary heart disease 0.01 -0.00
[ -0.22; 0.25] [ -0.25; 0.24]
CVD: Statins upon coronary heart disease -0.11 -0.16
[ -0.32; 0.11] [ -0.39; 0.08]
CVD: Anti-hypertensive therapy upon coronary heart disease and hypertension 0.83* 0.53
[ 0.14; 1.52] [ -0.19; 1.25]
Dementia: Prevalence -0.52 0.17
[ -1.45; 0.40] [ -0.77; 1.11]
Dementia: B12 and TSH 0.24 -0.34
[ -0.27; 0.75] [ -0.88; 0.20]
T2D: Prevalence 0.39* 0.10
[ 0.03; 0.74] [ -0.32; 0.52]
T2D: HbA1c -0.22* -0.28* -0.29*
[ -0.32; -0.12] [ -0.40; -0.17] [ -0.38; -0.21]
T2D: Ophtalmological examination 0.20* 0.24* 0.20*
[ 0.05; 0.36] [ 0.07; 0.40] [ 0.06; 0.33]
T2D: Fundus examination -0.37* -0.35* -0.36*
[ -0.56; -0.18] [ -0.56; -0.15] [ -0.52; -0.20]
T2D: Triglycerides and cholesterol 0.01 0.02
[ -0.08; 0.09] [ -0.07; 0.11]
T2D: Hypertension, nepropathy and A -0.06 -0.04
[ -0.27; 0.15] [ -0.25; 0.17]
T2D: Serum-creatinin 0.31* 0.23* 0.22*
[ 0.19; 0.42] [ 0.10; 0.36] [ 0.13; 0.31]
Osteoarthritis: Prevalence 0.23 0.32 0.23
[ -0.09; 0.54] [ -0.03; 0.67] [ -0.00; 0.47]
Osteoporosis: Prevalence 0.02 0.13
[ -0.39; 0.43] [ -0.29; 0.54]
Prevention: Influenca vaccination -0.47 -0.19
[ -1.67; 0.73] [ -1.43; 1.06]
Prevention: Mammography -0.82* -0.96* -0.92*
[ -1.14; -0.51] [ -1.33; -0.59] [ -1.21; -0.63]
Prevention: Faecal occult blood test -1.78* -1.02 -1.05
[ -3.34; -0.21] [ -2.61; 0.57] [ -2.38; 0.29]
Prevention: Men's cancer screening -0.03 -0.23
[ -0.50; 0.44] [ -0.69; 0.24]
Prevention: Skin-cancer screening 0.01 -0.32
[ -2.35; 2.38] [ -2.74; 2.10]
Depression: Prevalence 0.60* 0.19
[ 0.26; 0.94] [ -0.26; 0.65]
Depression: Anti-depressive pharmacotherapy -0.17 -0.03
[ -0.35; 0.01] [ -0.23; 0.17]
No. of variables 14 10 40 15 3 82 34
Num. obs. 407 407 407 407 407 407 407
R2 0.28 0.11 0.38 0.16 0.00 0.56 0.53
Adj. R2 0.25 0.09 0.32 0.13 -0.00 0.45 0.49
AIC 2697 2776 2686 2759 2807 2634 2563
* 0 outside the confidence interval.